Terapevticheskii arkhiv
https://ter-arkhiv.ru/0040-3660
<p>Peer-review medical journal</p> <p><strong>Editor-in-Chief</strong>: Irina E. Chazove, MD, Dr.Sci. (Med.), Professor.</p> <p><strong>Indexation</strong>: RSCI (Russian Science Citation Index), PubMed/Medline, Index Medicus, Scopus, Web of Science Core Collection (Science Citation Index Expanded), Web of Science (Russian Science Citation Index - RSCI, Current Contents Connect, BIOSIS Previews), Google Scholar, Ulrich's Periodicals Directory, WorldCat.</p> <p><strong>Open Access & Publication Frequency</strong>: Platinum Open Access; 12 issues annualy (monthly journal).</p> <p><strong>ISSN</strong> 0040-3660 (Print), <strong>ISSN</strong> 2309-5342 (Online)</p>LLC Obyedinennaya Redaktsiyaru-RUTerapevticheskii arkhiv0040-3660<p>Authors who publish with this journal agree to the following terms:</p> <ol> <li>Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/" target="_blank" rel="noopener">Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Licensee</a> (CC BY-NC-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.</li> <li>Authors are able to use published version of the work for educational and not-for-profit proposes (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.</li> <li>Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See <a href="http://opcit.eprints.org/oacitation-biblio.html" target="_new">The Effect of Open Access</a>).</li> </ol> <p>All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical '<em>TERAPEVTICHESKII ARKHIV</em>'.</p> <div><details> <summary><strong>READ the details online</strong> (tap to see in details)</summary> <h4>Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical '<em>TERAPEVTICHESKII ARKHIV</em>'</h4> <p>The editorial board of the '<em>TERAPEVTICHESKII ARKHIV</em>' (ISSN 0040-3660 (Print), ISSN 2309-5342 (Online), mass media registration certificate ПИ № ФС 77 - 31249 dated 29.02.2008) represented by editor-in-chief Irina E. Chazova, acting under the Charter (hereinafter referred to as the Licensee), on one side, and the representative of the authors' team (hereinafter referred to as the Licensor), on the other side, hereinafter together referred to as Parties, have concluded this agreement (hereinafter referred to as Agreement) on publication of scientific work (hereinafter referred to as Work) in the <em>'<em>TERAPEVTICHESKII ARKHIV</em>'</em> (hereinafter referred to as the Journal) under the terms and conditions set forth below.</p> <ol> <li><strong>General provisions</strong> <ul> <li>This Agreement under clause 2 Art. 437 of the Civil Code of the Russian Federation is a public offer (hereinafter referred to as Offer), full and unconditional acceptance of which following Art. 438 of the Civil Code of the Russian Federation is deemed to be the submission by the Licensor of the Work by uploading it to the online electronic system for accepting manuscripts for review in the relevant section of the Journal's website on the information and telecommunication network Internet (hereinafter referred to as the Internet).</li> </ul> </li> <li><strong>Terms used in the Agreement</strong> <ul> <li>Acceptance of the Offer is full and unconditional acceptance of the Offer on the terms and conditions specified in paragraph 4 of the Agreement (the Licensor accepts the Offer by sending an Application to the Licensee — uploading the Work and accompanying materials in the online electronic system of acceptance of articles for review in the relevant section of the Journal's website on the Internet).</li> <li>The Journal is a peer-reviewed scientific journal registered as a mass medium in the register of Roskomnadzor (the mass media registration certificate ПИ № ФС 77 - 31249 dated 29.02.2008).</li> <li>The Application is an electronic application of the Licensor to the Licensee for publication of the Work in the Journal by uploading the Work and accompanying materials to the online electronic system of accepting manuscripts for review in the relevant section of the Journal's website on the Internet.</li> <li>The Licensor is an individual, a representative of the authors' group, by whose creative work the Work was created.</li> <li>The Licensee is the Editorial Board of the mass medium '<em>TERAPEVTICHESKII ARKHIV</em>' represented by the Editor-in-Chief.</li> <li>Metadata is information in Russian and English intended for inclusion in International Scientific Databases (ISDB), namely:<br /> <ul> <li>the title of the Work;</li> <li>information about the authors (last name, first name, patronymic of the author (authors) in full, place of work of each author indicating his/her postal address, contact information (email), ISDB identifiers for each author;</li> <li>abstract;</li> <li>keywords;</li> <li>subject heading: UDC or other library and bibliographic classification and subject indexes;</li> <li>bibliographic list (references).</li> </ul> </li> <li>Offer is this document (offer to the Licensor) to publish the Work by posting it on the Journal's website.</li> <li>Work is the result of fundamental and/or applied scientific research in the form of scientific material, review scientific material, scientific communication, bibliographic review on certain topics of scientific research, historical note on figures of Russian and foreign science, submitted by the Author for publication in the Journal.</li> <li>Publication is placement of an Article in the Journal.</li> <li>Article is a Work that has undergone the process of review and</li> <li>editorial processing.</li> <li>Parties are the Licensor and the Licensee.</li> <li>Requirements for manuscripts are the requirements for materials published in the Journal, available in the "Authors" section of the Journal's website on the Internet.</li> </ul> </li> <li><strong>Subject of the Agreement (Offer)</strong> <ul> <li>Under this Agreement, the Licensor grants to the Licensee an exclusive license to use the Work, free of charge, within the limits and for the period specified in the Agreement.</li> <li>The Licensor warrants that it holds the exclusive copyright in the Work transferred to the Licensee.</li> </ul> </li> <li><strong>Rights and obligations of the Parties</strong> <ul> <li>The Licensor grants c Licensee the following rights for the duration of the exclusive rights to the Work:<br /> <ul> <li>the right to review and, if the manuscript of the Work is accepted, to make literary and scientific editing and proofreading;</li> <li>the right to reproduce the Work (to publish, make public, duplicate, replicate or otherwise reproduce the Work) without limitation of the number of copies (upon that each copy of the Work shall contain the name of the author of the Work);</li> <li>the right to distribute the Work by any means throughout the world;</li> <li>the right to post the Work in electronic format on the Journal's website;</li> <li>the right to translate the Work into any languages;</li> <li>the right of public disclosure;</li> <li>the right to use the metadata (title, author's (copyright holder's) name, abstracts, bibliographic materials, etc.) of the Works by disseminating and making available to the public, processing, and systematization, as well as inclusion in various databases and information systems on the Internet in the public domain;</li> <li>the right to assign, on contractual terms, some or all of the rights obtained hereunder to third parties without payment of remuneration to the Work.</li> </ul> </li> <li>Other rights not expressly granted to the Licensee hereunder, including patent rights in any processes, methods, or techniques and the like described by the Licensor in the Work, as well as trademark rights, are reserved by the Licensor and other rights holders.</li> <li>The Licensee has the right to request, and the Licensor undertakes to provide, if necessary, source (raw) data as well as other information and documents required for an objective review of the manuscript of the Work and compliance with ethical standards of scientific and medical publications therein (e.g., copies of the ethics committee resolution, informed patient consent, etc.).</li> <li>The Licensee undertakes to observe the copyrights stipulated by the current legislation, the Licensor's rights, as well as to protect them and to take all possible measures to prevent infringement of copyrights by third parties.</li> <li>The territory in which the rights to the Works may be used is unlimited.</li> <li>The Licensor also grants the Licensee the right to store and process the following personal data without a time limit for all authors of the Work:<br /> <ul> <li>name, patronymic, last name;</li> <li>date of birth;</li> <li>educational background;</li> <li>information on the place of work and the position held;</li> <li>information on the published works of literature, science and art;</li> <li>the international identification number ORCID and the data contained therein.</li> </ul> </li> <li>Personal data are provided for their storage and processing in various databases and information systems, their inclusion in analytical and statistical reporting, the creation of a reasonable connection between the objects of science, literature, and art with personal data, etc.</li> <li>The Licensee has the right to transfer this data for processing and storage to third parties, provided that the Licensee notifies the third party of this fact and provides information about the third party (name and address) to the Licensor.</li> </ul> </li> <li><strong>Warranties and responsibilities of the Parties</strong> <ul> <li>At the time of signing this Agreement, the Licensor warrants that it holds the exclusive copyright in the Work transferred to the Licensee and that at the time of granting the Licensee the right to the Work, it has not given any instructions that would conflict with the rights transferred to the Licensee under the Agreement.</li> <li>The Licensor warrants that this Work has not been previously contractually transferred to anyone for reproduction or other use.</li> <li>The Licensor warrants that the Work does not contain any copyrighted material of which it is not the copyright holder. If the Work incorporates copyrighted material owned by another person, the Licensor undertakes to obtain at its own cost and expense all necessary rights to use this material in the Work and to bear the property liability associated with the unauthorized use in the Work of copyrighted material belonging to other authors or other right holders. The Licensor agrees to indemnify the Licensee against all third-party claims caused by or arising out of any breach of the warranties and obligations stipulated above.</li> <li>The Licensor confirms that it has read and understood the instructions for authors and the publication ethics for authors and typical examples of violations (including plagiarism, multiple submissions, improper authorship, and other examples of violations).</li> <li>If any material in the Work is found which is not owned by the Licensor, or any other infringement in accordance with cl. 3.4. the Licensor may be denied placement of the Work. If the Work has already been published at the time such material or infringement is discovered, it may be revoked (retracted) or withdrawn entirely from the electronic version, in accordance with international and national guidelines and recommendations on publication ethics of scientific journals (including <a href="https://publicationethics.org/">https://publicationethics.org</a> and <a href="https://rasep.ru/sovet-po-etike/deklaratsiya">https://rasep.ru/sovet-po-etike/deklaratsiya</a>).</li> <li>The Licensee is not account for the content of the Work. In the event of disputes concerning the rights to the work, the Licensor takes full responsibility for the settlement of these disputes and bears moral and financial responsibility.</li> <li>The Parties shall be liable, under the current legislation of the Russian Federation, for non-fulfillment or improper fulfillment of their obligations under this Agreement.</li> <li>The Party that improperly performs or fails to perform its obligations hereunder shall be obliged to reimburse losses incurred by the other Party, including lost profits.</li> </ul> </li> <li><strong>Acceptance of the Offer and conclusion of the Agreement Term of the Agreement</strong> <ul> <li>This Agreement shall become effective on the date of its conclusion when the Licensor accepts the Offer by sending the Application to the Licensee and shall be valid for the duration of the exclusive rights to the Article.</li> <li>Acceptance of the Offer by the Licensor creates an Agreement concluded in writing (Articles 438 and 1286.1 of the Russian Federation Civil Code) on the Offer conditions.</li> </ul> </li> <li><strong>Procedure for amendment and termination of the Agreement</strong> <ul> <li>The Licensee has the right to unilaterally change the terms of this Agreement by notifying the Licensor through the Journal's website or by sending a notice via e-mail to the e-mail address of the Licensor specified in the Application of the Licensor at least ten (10) calendar days prior to the effective date of the relevant changes. The amendments shall become effective on the date specified in the notice.</li> <li>In case the Licensor disagrees with the changes in the terms of this Agreement, the Licensor has the right to send the Licensee a written notice of withdrawal from this Agreement by uploading the notice to the online electronic system of accepting articles for review available in the relevant section of the Journal's website) or sending the notice to the official e-mail address of the Editorial Board on the Internet)</li> <li>This Agreement may be brought to an early termination:<br /> <ul> <li>by mutual consent of the Parties at any time;</li> <li>on other grounds stipulated by this Agreement.</li> </ul> </li> <li>The Licensor has the right to unilaterally withdraw from this Agreement by giving the Licensee a corresponding notice in writing not less than sixty (60) calendar days prior to the intended date of publication of the Work by the Licensor in the Journal.</li> <li>Termination of the Agreement for any reason shall not relieve the Parties from liability for breach of the terms and conditions of the Agreement arising during the term of its validity.</li> </ul> </li> <li><strong>Liability</strong> <ul> <li>For non-fulfillment or improper fulfillment of their obligations under the Agreement the Parties shall be liable in accordance with the current legislation of the Russian Federation.</li> <li>All information provided by the Licensor must be accurate. The Licensor is responsible for the accuracy and completeness of the information transferred to the Licensee. When using inaccurate information received from the Licensor, the Licensee shall not be liable for any adverse consequences caused by its actions based on the provided inaccurate information.</li> <li>Concerning the content of the Article, the Licensor shall be solely responsible for compliance with the requirements of Russian legislation on advertising, protection of copyright and related rights, protection of trademarks and service marks, and protection of consumer rights.</li> <li>The Licensee shall not have any liability under the Agreement:<br /> <ul> <li>for any actions resulting directly or indirectly from misconduct of the Licensor;</li> <li>for any losses of the Licensor regardless of whether the Licensee could have foreseen the possibility of such losses or not.</li> </ul> </li> <li>The Licensee shall be exempt from liability for breach of the terms and conditions of the Agreement if such breach is caused by force majeure, including actions of public authorities (including the adoption of legal acts), fire, flood, earthquake, other natural disasters, power outage and/or computer network failures, strikes, civil unrest, riots, any other circumstances.</li> </ul> </li> <li><strong>Dispute settlement procedure</strong> <ul> <li>Disputes and disagreements shall be resolved by the Parties by negotiations and in case of failure to reach an agreement following the current legislation of the Russian Federation.</li> <li>In case of unresolved disputes between the Parties, the disputes shall be resolved in the court according to the location of the Licensee following the current legislation of the Russian Federation.</li> </ul> </li> <li><strong>Other terms and conditions</strong> <ul> <li>Any notifications, messages, requests, etc. (except for the documents to be sent in the form of original copies under the legislation of the Russian Federation) shall be deemed received by the Licensor if they have been transmitted (sent) by the Licensee via the Journal's website (including by publication), by fax, by e-mail specified in the Application and other communication channels. The Parties acknowledge the legal validity of notices, messages, requests, etc., transmitted (sent) in the abovementioned ways.</li> <li>In case of claims against the Licensee related to the infringement of exclusive copyright and other intellectual property rights of third parties in the creation of the Article or in connection with the conclusion of this Agreement, as well as in connection with the use of the Work by the Licensee in accordance with the Agreement, the Licensor shall be obliged:<br /> <ul> <li>immediately upon receipt of the Licensee's notice, take measures to settle disputes with third parties, if necessary, enter into litigation on the side of the Licensee and take all actions in its power to exclude the Licensee from the list of defendants;</li> <li>reimburse to the Licensee the legal costs incurred, costs and losses caused by the application of measures of securing the claim and execution of a court decision, and amounts paid to a third party for violation of exclusive copyright and other intellectual property rights, as well as other losses incurred by the Licensee due to non-compliance with the guarantees provided by the Licensor under this Agreement.</li> </ul> </li> </ul> </li> </ol> <ol start="11"> <li><strong>Registered office address and administrative details of the Licensee </strong> <ul> <li>Editor-in-Chief, <em>'TERAPEVTICHESKII ARKHIV'</em><br />Irina E. Chazova</li> <li>Publisher: Consilium Medicum</li> <li>Address: Moscow, ul. Alabyan d. 13, k. 1, etazh 3, pom. XXVIIIA</li> <li>Taxpayer Identification Number (INN): 7714456747; <br />Tax Registration Reason Code (KPP): 774301001; <br />Primary State Registration Number (OGRN): 1197746753137; <br />Russian Business and Organization Classification (OKPO): 42874998.</li> </ul> </li> </ol> </details></div>Possibilities for improving hospital and remote forecasts for unstable angina
https://ter-arkhiv.ru/0040-3660/article/view/71285
<p>Unstable angina (UA) is a type of acute coronary syndrome (ACS) without ischemic myocardial damage. The main criterion for the diagnosis of UA in ACS is the absence of changes in the concentration of cardiac troponin in the patient’s blood. When the volume of myocardial damage is small, it may be difficult to detect myocardial infarction in a patient using low-sensitivity tests for determining of cardiac troponin in the blood. This issue may lead to overdiagnosis of UA in patients with non-STE ACS. Optimal drug therapy and revascularization of the coronary arteries significantly reduce the risk of death and the development of myocardial infarction both in the hospital and in the long-term period in patients with UA. Outpatient follow-up and provision of free of charge medications to patients may reduce long-term mortality after an episode of UA.</p>Sergey A. BoytsovSergei I. Provatorov
Copyright (c) 2024 Consilium Medicum
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-01-252024-01-2596151010.26442/00403660.2024.01.202555The effect of taking antibacterial therapy on the outpatient stage and outcomes of community-acquired pneumonia in Tomsk hospitals
https://ter-arkhiv.ru/0040-3660/article/view/119061
<p><strong>Background. </strong>Community-acquired pneumonia (CAP) remains one of the most common diseases requiring urgent hospitalization, with a significant part of patients already receiving antibiotics before admission to the hospital.</p> <p><strong>Aim. </strong>To assess the relationship between outpatient antibacterial therapy and in-hospital mortality and the severity of the CAP.</p> <p><strong>Materials and methods. </strong>The retrospective study included the data of adult patients with CAP who were hospitalized in Tomsk from January 1 to December 31, 2017.</p> <p><strong>Results. </strong>Among 1412 patients, 22.2% received antibiotics before admission to the hospital, the proportion of deaths in this group was significantly lower – 3.8% compared with 10.6% among patients without antibiotic therapy (p<0.001). Subjects who received antibiotics on outpatient basis were less likely to require being in the intensive care unit and administering vasopressors, in contrast to patients without prior antibiotic therapy: 5.1 and 10.6% (p=0.003); 7.1 and 4.7% (p=0.018) respectively. In patients with severe CAP on a scale IDSA/ATS, only 11.8% of cases were detected with antibiotics before hospitalization, while in mild CAP the frequency of administration was 16.6% (p<0.001).</p> <p><strong>Conclusion. </strong>Ambulatory antibacterial therapy had a positive effect on the subsequent course and outcomes of CAP in a hospital setting. Patients had a predominantly mild course of the disease, needing for vasopressors, and being in the intensive care unit, but was not consistent with the need for invasive mechanical ventilation.</p>Daria A. VinokurovaEvgeny S. KulikovOlga S. KobyakovaElena A. StarovoytovaIvan A. DeevSergey V. FedosenkoGeorgy E. ChernogoryukEkaterina A. ChernyshevaNikolay D. Yarovoy
Copyright (c) 2024 Consilium Medicum
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-01-252024-01-25961111610.26442/00403660.2024.01.202574Clinical features of coronary artery disease and 5-year survival of patients after myocardial infarction against the background of depressive disorders
https://ter-arkhiv.ru/0040-3660/article/view/71330
<p><strong>Aim. </strong>To assess the features of the clinical picture of coronary artery disease (CAD) and the prognosis of patients with myocardial infarction with depressive disorder (DD).</p> <p><strong>Materials and methods. </strong>We examined 101 patients with stable CAD who had myocardial infarction more than six months ago: 67 CAD patients with depression (Group 1) and 34 CAD patients without depression (Group 2). The clinical picture of CAD was assessed by complaints, angina self-monitoring diaries, and exercise tests. The presence and severity of DD was determined using psychometric scales: BDI (Beck Depression Scale), HADS (Hospital Anxiety and Depression Scale) and the opinion of a psychiatrist. Five-year survival information was obtained through telephone interviews with patients and their relatives.</p> <p><strong>Results. </strong>In patients with CAD and DD in comparison with patients without DD self-monitoring diaries revealed more frequent angina attacks: 9 [6; 12] vs 6 [4; 7] per week (p=0.0001), the greater need for sublingual nitrates: 2 [0; 9] pills vs 0 [0; 4] pills (p=0.0001). DD significantly reduced exercise tolerance: 370 [250; 450] meters vs 435 [350; 500] meters using the six-minute walk test (p=0.04), according to the results of bicycle ergometry – 50 [25; 75] W vs 75 [50; 75] W (p=0.03). After 5 years of follow-up patients with comorbidities (CAD and DD) had a greater number of deaths: 13 (19.4%) vs 2 (5.9%), respectively, survived – 54 (80.6%) vs 32 (94.1%) (Gehan–Wilcoxon test, p=0.04).</p> <p><strong>Conclusion. </strong>The comorbidity CAD and DD leads to a worsening of the clinical course of CAD and prognosis, which actualizes the need for verification of the diagnosis of DD and timely prescription of antidepressant therapy.</p>Tatiana G. NonkaElena V. LebedevaAlexey N. Repin
Copyright (c) 2024 Consilium Medicum
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-01-252024-01-25961172110.26442/00403660.2024.01.202560Inflammation and myocardial fibrosis: is there a relation with left bundle branch block
https://ter-arkhiv.ru/0040-3660/article/view/628954
<p><strong>Aim. </strong>To assess myocardial changes during left bundle branch block (LBBB) in patients with dilated cardiomyopathy (DCM) and in structurally normal hearts.</p> <p><strong>Materials and methods. </strong>Seventy three patients with clinic-instrumental signs of DCM, were divided into 2 groups with LBBB (group 1; n=41) and without LBBB (group 2; n=32). Moreover, 15 patients with LBBB with no signs of structural heart diseases (group 3) and 10 healthy subjects were included in the study. Fibrosis assessment and the inflammation detection was performed by cardiovascular magnetic resonance (CMR). The inflammation in 15 patients from group 1 and 16 patients from group 2 was confirmed by endomyocardial biopsy (EMB). Moreover, the level of transforming growing factor β1was assessed in serum of all patients and healthy subjects (TGF-β1).</p> <p><strong>Results. </strong>The diffuse inflammatory process was defined in 46.7% cases of group 1 according to EMB data. The frequency of inflammation detection in groups 1 and 2 was comparable in EMB analyses (p=0,64) and CMR analyses (12,2% positive cases in group 1 vs 50% in group 2; p=0,18). The frequency of focal left ventricular fibrosis and intramural scar in the interventricular septum (“stria”) was also comparable in groups 1 and 2: 16 (39%) positive cases with focal fibrosis in group 1 versus 17 (53%) cases in group 2; p=0,35 and 6 (14,6%) cases with intramural scar in group 1 versus 7 (22%) in group 2; p=0,12. Patients from group 3 demonstrated no late gadolinium enhancement on CMR images but increased TGF-β1 level in the serum.</p> <p><strong>Conclusion. </strong>Focal myocardial fibrosis is not related to the LBBB. Patients with idiopathic LBBB are characterized by increased TGF-β1 level with no myocardial fibrosis. Diffuse inflammation in LBBB-DCM patients may contribute to the progression of systolic dysfunction but is not the reason for LBBB formation.</p>Elena M. RimskayaOlga V. StukalovaOlga P. AparinaNataliia A. MironovaTatiana V. KuznetsovaPetr V. ChumachenkoSergey P. Golitsyn
Copyright (c) 2024 Consilium Medicum
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-01-252024-01-25961222810.26442/00403660.2024.01.202575Dynamics of hospital mortality in COVID-19 pandemia
https://ter-arkhiv.ru/0040-3660/article/view/568620
<p><strong>Background. </strong>During the pandemic of coronavirus infection (COVID-19) caused by a virus SARS-CoV-2 there has been significant variability in symptoms of the disease over time, severity of the course and in particular hospital mortality. Several SARS-CoV-2 variants have been identified such as Alpha, Delta, Omicron and others.</p> <p><strong>Aim. </strong>To investigate the hospital mortality in patients with different strain variants during the period from April 2020 to April 2022. All included patients had moderate to severe COVID-19-associated pneumonia requiring hospitalization.</p> <p><strong>Materials and methods. </strong>In this retrospective, conclusive, non-randomized, non-controlled study 4854 clinical records of hospitalized patients with Alpha (n=2400, April – December 2020), Delta (n=1722, 2021) and Omicron (n=627, January – April 2022) variants were investigated.</p> <p><strong>Results. </strong>Hospital mortality is 6% in Alpha variant patients (6%), 5.7% in Delta and significantly lower in Omicron (1.5%; p<0,001). Cardiovascular disease (arterial hypertension, coronary heart disease, chronic heart failure), diabetes mellitus and chronic kidney disease were risk factors for death in Alpha and Delta, but not in Omicron. There was also a significant decrease in the duration of hospitalization with strains Delta [7 days (5; 9)] and Omicron [7 (5; 11)] compared with Alpha [11 (9; 13); p<0,001], and differences in factors the risk of mortality between the tested COVID variants.</p> <p><strong>Conclusion. </strong>Thus, differences in mortality and risk factors for death between COVID-19 variants could be shown in our cohort.</p>Diana F. GareevaIrina A. LakmanAlexander A. AgapitovLiana F. SadikovaParuir A. DavtianValeriia L. KayumovaGuzel M. NurtdinovaElena A. BadykovaMagomed S. KurbanovIslam R. IdigovLukas FiedlerLukas-Jaroslaw MotlochАnna-Maria DieplingerVenera M. TimiryanovaNaufal Sh. Zagudullin
Copyright (c) 2024 Consilium Medicum
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-01-252024-01-25961293510.26442/00403660.2024.01.202558The effectiveness of hardware CPAP therapy in heart failure with preserved left ventricular ejection fraction and obstructive sleep apnea syndrome
https://ter-arkhiv.ru/0040-3660/article/view/281830
<p><strong>Aim. </strong>To evaluate the effectiveness of hardware Continuous Positive Airway Pressure therapy (CPAP therapy) and its likely predictors in patients with heart failure with preserved ejection fraction (HFpEF) associated with obstructive sleep apnea syndrome (OSAS).</p> <p><strong>Materials and methods. </strong>The study involved 207 men with HFpEF and OSAS (apnea/hypopnea index >15 per hour) who did not initially have ischemic disease and other structural heart pathology. At inclusion in the study, polysomnography and echocardiography were performed with an assessment of diastolic function and global longitudinal deformation of the left ventricular myocardium, as well as a 6-minute walk test (6MWT) and the level of the brain natriuretic peptide precursor (NT-proBNP) in the blood was determined. 80 patients received hardware CPAP the rapy, 127 patients made up the control group. After 12 months, 6MWT was repeated, NT-proBNP was determined, and clinical outcomes were assessed retrospectively.</p> <p><strong>Results. </strong>The CPAP group had 16% fewer hospitalizations (p=0.011 [95% confidence interval – CI 4.29]) and showed a trend towards an increase in the 6MWT distance (p=0.065). To assess the likely predictors of the effectiveness of CPAP therapy, a subgroup of “responders” was identified, characterized by an increase in the distance according to the 6MWT, a decrease in the level of NT-proBNP, and the absence of adverse clinical events during the observation period. There were significant differences between responders and non-responders in apnea/hypopnea index (p=0.01 [95% CI -10.6; -2.5]), global longitudinal deformation of the left ventricular myocardium (p=0.05 [95% CI -4.7; 0]), diastolic function E/A (p=0.02 [95% CI -0.1; 0]).</p> <p><strong>Conclusion. </strong>CPAP therapy improves clinical outcomes and functional status in patients with OSAS-associated HFpEF. The predictive model built using the identified efficacy predictors can be used to develop a personalized treatment algorithm for this cohort of patients.</p>Alexey V. YakovlevIvan A. EfremovNatalia F. YakovlevаSergey N. ShilovAndrey N. RyabikovAlexander T. TeplyakovElena V. GrakovaKristina V. KopevaIlya V. Shirokikh
Copyright (c) 2024 Consilium Medicum
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-01-252024-01-25961364110.26442/00403660.2024.01.202563Relationships of doctors and patients of the infection hospital during the 1st and 2nd waves of the COVID-19 pandemic
https://ter-arkhiv.ru/0040-3660/article/view/472163
<p><strong>Aim. </strong>To conduct a comparative analysis of the relationship between doctors and patients in a regional infectious diseases hospital to combat the complications of COVID-19 during the 1st and 2nd waves of the pandemic.</p> <p><strong>Materials and methods. </strong>The basis of the study was the infectious diseases hospital deployed in the City Clinical Hospital No. 5 in Nizhny Novgorod. The hospital treated patients with complications of coronavirus infection with concomitant therapeutic or surgical pathology. The study was conducted taking into account the principles of robust management through questioning, on issues related to the social characteristics of patients and their subjective assessments of relationships with medical personnel. The scope of the study was 129 people.</p> <p><strong>Results. </strong>The study did not reveal any changes in the relationship between medical workers and patients; both in the 1st and in the 2nd wave of the pandemic, they were built on mutual respect and empathy: medical workers do their best to support patients, the latter, in turn, understand the difficulties of staff work in an infectious diseases hospital and feel gratitude. The established facts are convincing proof of the high level of readiness of medical organizations and their employees to work in extreme conditions associated with a tense epidemic situation.</p> <p><strong>Conclusion. </strong>Thus, the results of this study indicate the formation in the 1st wave of the pandemic of a model of relationships built on the principles of mutual trust, support and avoidance of conflicts between doctors and patients of the regional infectious diseases hospital and the preservation of this model during the 2nd wave of the pandemic.</p>Tatyana E. RomanovaOlga P. AbaevaNadezhda V. PrisyazhnayaSergey V. RomanovVitaly A. Berdutin
Copyright (c) 2024 Consilium Medicum
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-01-252024-01-25961424410.26442/00403660.2024.01.202562Combination therapy for productive cough in acute respiratory viral infection (ARVI) and acute bronchitis in real clinical practice
https://ter-arkhiv.ru/0040-3660/article/view/628959
<p><strong>Aim. </strong>To evaluate effectiveness and safety of combination drug containing ambroxol, guaifenesin and levosalbutamol (Ascoril LS), oral solution, in comparison with monocomponent drugs in the treatment of productive cough in adult patients with acute respiratory viral infection (ARVI) and acute bronchitis.</p> <p><strong>Materials and methods. </strong>Open randomized study included patients with clinical symptoms of ARVI and acute bronchitis, having productive cough with difficulty in sputum discharge. 160 patients were randomized into 4 groups that received the study drug or comparison drugs (ambroxol, acetylcysteine, Rengalin) 3 times a day for 20 days. After 5, 10, 15 and 20 days of treatment, the doctor assessed subjective complaints and effectiveness of therapy. The primary endpoint was the proportion of patients with high and very high efficacy, recovery from work, and clinically significant cardiovascular events.</p> <p><strong>Results. </strong>Satisfaction with clinical effect of therapy with Ascoril LS was noted by 96% of patients, tolerability and ease of administration by 99%. 97% of patients are satisfied with price/quality ratio. The overall percentage of satisfaction with treatment Ascoril LS was 99%. Tolerability of therapy was assessed by all patients as good, without the development of significant adverse events. During therapy for productive cough, a significant decrease in cough was noted in Ascoril LS group already on the 5th day of therapy (57%) and subsequently at all follow-up visits. Restoration of working capacity of patients in Ascoril LS group due to complete regression of productive cough was established in 50% of patients on the 5th day of treatment. On days 10 and 15, 75% and 90% of patients, respectively, were able to begin work due to complete relief of cough, which is significantly more compared to other treatment groups. It is important that in all cases Ascoril LS was prescribed at the very beginning of the disease, which made it possible to achieve the described results</p> <p><strong>Conclusion. </strong>The effectiveness of a new combination drug containing ambroxol, guaifenesin and levosalbutamol for the treatment of productive cough in adult patients with ARVI and acute bronchitis exceeds the effectiveness of monocomponent therapy with comparator drugs. The safety profiles of the study drug and comparison drugs were comparable, including in patients with cardiovascular risk.</p>Igor V. LeshchenkoNatalia A. Esaulova
Copyright (c) 2024 Consilium Medicum
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-01-252024-01-25961465210.26442/00403660.2024.01.202584Vaping use-associated lung injury in a teenager. Case report
https://ter-arkhiv.ru/0040-3660/article/view/472069
<p>In the last 10–15 years, especially among young people, there has been an increase in the prevalence of vaping, which partially replaces the smoking of conventional cigarettes. The chemicals in vape liquids can provoke the development of non-infectious inflammatory pneumonitis. Symptoms of the disease usually appear within a few months after the start of smoking electronic cigarettes. Vape-associated lung disease is a clinical diagnosis and is established after the exclusion of other respiratory diseases. The article describes a clinical case of vape-associated lung injury in a 17-year-old teenager.</p>Irina V. OzerskaiaAlexander B. MalakhovAlyona Yu. SedovaVeronika D. DenisovaVeronika A. BarinovaIrina V. Grebeneva
Copyright (c) 2024 Consilium Medicum
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-01-252024-01-25961535710.26442/00403660.2024.01.202561Therapies of chronic thromboembolic pulmonary hypertension: A review
https://ter-arkhiv.ru/0040-3660/article/view/569331
<p>The article addresses therapies for chronic thromboembolic pulmonary hypertension (CTEPH). The main challenges of patient management at various stages of diagnosis and treatment and the prevalence and pathogenesis of CTEPH are described. Immediate and long-term outcomes after treatment are evaluated. The study aims to present current therapies for CTEPH.</p>Oksana Ya. VasiltsevaAlexander G. EdemskiyDevran F. ZeinalovElena N. KliverWladimir Yu. UssovDenis S. GrankinDmitry A. SirotaAleksandr M. Chernyavskiy
Copyright (c) 2024 Consilium Medicum
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-01-252024-01-25961586210.26442/00403660.2024.01.202557Pharmacogenetics of dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes mellitus: A review
https://ter-arkhiv.ru/0040-3660/article/view/628985
<p>The review addresses publications on genetic polymorphisms that potentially impact the effectiveness of therapy with hypoglycemic drugs of the dipeptidyl peptidase-4 inhibitor group. The literature was searched in the PubMed database from 2017 to 2023. Polymorphisms of several genes (GLP1R, TCF7L2, DPP-4, KCNQ1, KCNJ11, PNPLA3, PRKD1) are associated with the pharmacokinetic values and efficacy of dipeptidyl peptidase-4 inhibitors, which may be promising for personalizing the treatment of patients with type 2 diabetes mellitus.</p>Iuliia G. SamoilovaOlga E. VaizovaAnastasia E. StankovaMariia V. MatveevaDaria V. PodchinenovaDmitry A. KudlayAnastasiia A. BorozinetsTatyana A. FilippovaIvan R. GrishkevichAnastasia V. PartalaDiana A. Gerasimova
Copyright (c) 2024 Consilium Medicum
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-01-252024-01-25961636710.26442/00403660.2024.01.202553Efficacy, safety and prospects of using a combination of native type II collagen, methylsulfonylmethane, boswellic acids, vitamin C and vitamin D<sub>3</sub> in knee osteoarthritis: a resolution of the Expert panel
https://ter-arkhiv.ru/0040-3660/article/view/628963
<p>A meeting of the Expert Council on September 9, 2023 considered the last challenges in the treatment of osteoarthritis (OA) including OA in comorbid patients. Leading experts in rheumatology, traumatology and other relevant disciplines participated in the meeting. The key goal of Expert Council was the discussion of potential application of a combination of undenatured (native) type II collagen, methylsulfonylmethane, boswellic acids, vitamins C and D (Artneo complex) as a part of complex OA therapy. The experts concluded that Artneo for stage I–III knee OA patients is not just non-inferior in comparison with a combination of chondroitin sulfate and glucosamine hydrochloride but excels it in the decrease of magnetic resonance imaging synovitis markers and dynamics of Lequesne index for knee osteoarthritis severity. The proven efficacy and the favorable safety profile of 6-months Artneo course deserve the attention of medical community and the active implementation of Artneo complex into ambulatory practice, first of all, for the treatment of patients with mild or moderate synovitis and/or burdened with comorbidities.</p>Vadim I. MazurovLiudmila I. AlekseevaIrina B. BelyaevaIgor G. BelenkiyArtem L. BurulevInna Z. GaydukovaElena V. ZonovaOleg V. KalyuzhinOlga B. NesmeyanovaElvira N. OttevaEvgeniy A. Trofimov
Copyright (c) 2024 Consilium Medicum
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-01-252024-01-25961687410.26442/00403660.2024.01.202590History of the study of infective endocarditis in Russia
https://ter-arkhiv.ru/0040-3660/article/view/112396
<p>The history of the study of infective endocarditis in Russia is described in the article.</p>Julia L. KaraulovaElizaveta O. KotovaAlexandra S. PisaryukNikita M. PovalyaevZhanna D. Kobalava
Copyright (c) 2024 Consilium Medicum
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-01-252024-01-25961757910.26442/00403660.2024.01.202559